accepted in British Journal of Pharmacology

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro

SebastianSchloer, LindaBrunotte, AngelesMecate-Zambrano, ShuyuZheng, JingTang, StephanLudwigUrsulaRescher

My lab investigates key regulatory circuits that control the host inflammatory response, with a special emphasis on the complex molecular mechanisms and signaling events that lead to changes in cellular structure and function.

Receptors on the cell surface sense and respond to extracellular ligands and transmit the signals to the cell interior. Here, signal transduction pathways elicited through G-protein-coupled receptors (GPCRs), and the functional analysis of the Pattern Recognition Receptors, is a key aspect of our work (Pupjalis et al.; EMBO Mol. Med. 2011). Another major research topic is the late endosome, and its function as an important hub for the segregation of incoming cargo (Poeter et al.; Nature Commun. 2014) and as site of the endosomal escape for enveloped viruses (Kühnl et al.; mBio 2018), in particular Influenza A virus (in close cooperation with the Institute of Virology).


We are part of the SFB 1009 Breaking Barriers and SFB 1348 Dynamic Cellular Interfaces


PHI logoYou may also want to visit the website of PHI Muenster





Join us on facebook





Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine
SebastianSchloer, LindaBrunotte, JonasGoretzko, AngelesMecate-Zambrano, NadjaKorthals, VolkerGerke, StephanLudwig, UrsulaRescher